[Dialysis Outcomes and Practice Patterns Study: data on the use of central venous catheters in chronic hemodialysis].
Central venous catheters are widely used as vascular accesses for chronic haemodialysis. Different factors may lead to catheter use, whether clinical such as emergency dialysis, or related to practices specific to each dialysis unit or country. The Dialysis Outcomes and Practice Patterns Study is an observational study of more than 10,000 representative patients treated by haemodialysis followed over a two-year period in the United States, Japan, and in five European countries (France, Germany, Italy, Spain, United Kingdom). DOPPS data from the United States and Europe about catheters are reported in this paper. Catheter use is less frequent in Europe than in the US, both in incident and prevalent patients, and in patients who have been seen by a nephrologist in the pre-dialysis period. Tunneled and untunneled catheters are each associated with a significantly higher frequency of access infection compared to native arteriovenous fistulae and grafts. Patients with important comorbidities such as diabetes, cardiovascular diseases, malnutrition or dementia are more likely to be dialysed with tunneled catheters. Furthermore, patients initiating hemodialysis with a tunneled catheter display higher mortality risk compared to patients starting hemodialysis with a permanent access. In summary, DOPPS data indicate that central venous catheters are used for chronic haemodialysis in patients with a high level of morbidity, and that their utilisation is associated to an additional risk, particularly of infection, and to a lower survival for tunneled catheters. Appropriate care should limit the utilisation of central venous catheters to clinically undisputable indications.
Combe
C
C
Service de néphrologie B, Centre hospitalier universitaire de Bordeaux, France. christian.combe@chu-bordeaux.fr
Pisoni
R L
RL
Port
F K
FK
Young
E W
EW
Canaud
B
B
Mapes
D L
DL
Held
P J
PJ
D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000706:statistics & numerical data; D005060:Europe; D006801:Humans; D007239:Infections; D007564:Japan; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D006435:Renal Dialysis; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States